The Janus-faced Nature of miR-22 in Hematopoiesis: Is It an Oncogenic Tumor Suppressor or Rather a Tumor-Suppressive Oncogene?
Open Access
- 12 January 2017
- journal article
- editorial
- Published by Public Library of Science (PLoS) in PLOS Genetics
- Vol. 13 (1) , e1006505
Abstract
Hematopoiesis is a complex, multistep process originating from hematopoietic stem cells and structured into different lineages. Cell fate decision is well organized and strictly regulated by extrinsic and intrinsic molecules (such as cytokines and transcription factors) whose deregulation is connected to leukemic transformation. In recent years, the importance of microRNAs in controlling hematopoiesis has been discussed [1]. Since their discovery in 1993 [2], micro-RNAs have been intensively studied in multidisciplinary research fields and have even attracted the attention of the pharmaceutical industry as potential therapeutic targets in various diseases. The first drugs based on microRNA inhibition have already been approved [3]. Of note, increasing numbers of scientific publications focus on their role in oncology. It has been shown that microRNAs have great impact on cancer initiation or prevention, and several candidates were described to act as either tumor suppressors or oncogenes. While certain microRNAs can act as either tumor suppressors or oncogenes in different tissues, the observation of contradictory functions of a single microRNA in the same tissue and even the same cell type is rare and unusual. Looking at the myeloid lineage in the hematopoietic system, miR-181a is such a candidate: while Hickey et al. postulated its tumor-suppressive function in acute myeloid leukemia (AML) [4], several other groups revealed the oncogenic potential of miR-181a in the myeloid background [5, 6]. And what about miR-22 in hematopoiesis? In 2013, Song et al. demonstrated that miR-22 expression is up-regulated in myelodysplastic syndrome (MDS) and in AML [7]. They disclosed its oncogenic potential using retroviral and transgenic mouse models that developed hematological malignancies (including myeloid leukemia) and showed that knockdown of miR-22 blocked proliferation in leukemic cells. Given its role as an oncogenic microRNA, additional studies would have been expected to explore the therapeutic potential in blocking miR-22 in MDS or in AML. Surprisingly, at the beginning of 2016, Jiang et al. observed a different function of miR-22 in myeloid cells [8]: they demonstrated its tumor-suppressive potential in various cell culture and in vivo systems and found lower expression of miR-22 in AML compared to healthy controls. Is it possible that miR-22 has two faces in one cell lineage? In September 2016's issue of PLOS Genetics, Shen et al. provided further insights into the complexity of miR-22 function during myelopoiesis and with respect to myeloid leukemia [9]. The authors demonstrated that miR-22 is up-regulated during monocytic differentiation inKeywords
This publication has 16 references indexed in Scilit:
- RETRACTED: The PU.1-Modulated MicroRNA-22 Is a Regulator of Monocyte/Macrophage Differentiation and Acute Myeloid LeukemiaPLOS Genetics, 2016
- miR-22 has a potent anti-tumour role with therapeutic potential in acute myeloid leukaemiaNature Communications, 2016
- PML/RARα-Regulated miR-181a/b Cluster Targets the Tumor Suppressor RASSF1A in Acute Promyelocytic LeukemiaCancer Research, 2015
- MiR-181 family: regulators of myeloid differentiation and acute myeloid leukemia as well as potential therapeutic targetsOncogene, 2014
- The Oncogenic MicroRNA miR-22 Targets the TET2 Tumor Suppressor to Promote Hematopoietic Stem Cell Self-Renewal and TransformationCell Stem Cell, 2013
- Treatment of HCV Infection by Targeting MicroRNANew England Journal of Medicine, 2013
- Lenalidomide-mediated enhanced translation of C/EBPα-p30 protein up-regulates expression of the antileukemic microRNA-181a in acute myeloid leukemiaBlood, 2013
- Evi1 is essential for hematopoietic stem cell self-renewal, and its expression marks hematopoietic cells with long-term multilineage repopulating activityJournal of Experimental Medicine, 2011
- MicroRNAs are shaping the hematopoietic landscapeHaematologica, 2011
- The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14Cell, 1993